109 results about "Antigen recognition" patented technology

Chimeric antigen receptors that include an antigen recognition domain; a spacer domain derived from a modified immunoglobulin Fc region having one or more mutations in its CH2 region resulting in impaired binding to an FcR; and an intracellular signaling domain.

The invention is directed to a conjugate having the general formula (I)Xn—P—YmBo  (I)with X is an detection moiety,P is a spacer unit,Y an antigen recognizing moiety,B an oligonucleotide comprising 2 to 100 nucleotide residuesand n, m, o are independent integers between 1 and 100wherein P and B are covalently bound to Y and X is covalently bound to P and wherein X is erasable.Further, the invention is directed to a library of such conjugates and a method of detecting target cells utilizing the conjugates or the library of conjugates.

The invention provides a chimeric antigen receptor for regulating and controlling a signal time sequence and application of the chimeric antigen receptor. The chimeric antigen receptor sequentially comprises a signal peptide, an extracellular domain, a transmembrane domain and an intracellular domain from an N terminal to a C terminal, the extracellular structural domain comprises an antigen recognition region and a hinge region; the intracellular domain comprises a costimulatory signal transduction region and a CD3 [zeta] intracellular region variant; the CD3 [zeta] intracellular region variant comprises three ITAMs, and the arrangement sequence of the ITAMs is ITAM3-ITAM2-ITAM1 from the N end to the C end. Compared with a conventional chimeric antigen receptor containing a wild CD3 zeta intracellular region, the chimeric antigen receptor provided by the invention can significantly enhance the functional activity of immune cells expressing the chimeric antigen receptor, which is specifically embodied in stronger multiplication capacity and durability, and significantly improves the antigen sensitivity and targeted killing efficacy.

Various embodiments of the invention provide binding agents for glypican-3 (GPC3), including antibodies or antigen-binding fragments thereof that bind to GPC3 and antigen recognizing receptors (e.g., CARs) that target GPC3 including cells that express GPC3. Embodiments of the i n vention also provide cells comprising such binding agents such as CAR T-cells, therapeutic compositions comprising such cells and methods of using one or more of the binding agents, cells or therapeutic compositions for the treatment of diseases or disorders associated with GPC3 expression such as various neoplastic diseases or disorders (e.g., hepatocellular carcinoma). Various embodiments of the invention also provide methods and systems for treati ng hepatocellular carcinoma (HCC) utilizing a combi nation of radiofrequency (RF) ablation and GPC3-targeted cell therapy. In certain embodiments, immune modulators, such as checkpoint inhibitors, may be co-administered to potentiate immune responses. Additionally, compositions and kits comprising RF ablation devices and GPC3-targeted cell therapy formulations are provided.

Disclosed is a nucleic acid encoding a chimeric antigen receptor comprising an extracellular domain including an antigen recognition domain consisting of a fully human single variable heavy chain (VH) domain that binds to a first epitope on B-cell maturation antigen (BCMA), a transmembrane domain, and an intracellular domain including a signaling domain.

This invention belongs to the field of antigen recognition technology, specifically relating to an antibody or its antigen-binding fragment that targets and recognizes mCD155, and its applications. The antibody targeting and recognizing mCD155 includes sequences as shown in SEQ ID NO:8 and SEQ ID NO:16 or as shown in SEQ ID NO:24 and SEQ ID NO:32; it has a strong binding affinity to the mCD155-his protein; and CAR-T cells constructed based on this antibody exhibit excellent killing (apoptotic) activity against mCD155-mediated tumors.

The purpose of the present invention is to provide a polypeptide capable of binding to protein L. Provided is a protein L-binding polypeptide comprising amino acid sequence 1, which is L1 sequence (such as the amino acid sequence represented by SEQ ID NO: 1) - antigen recognition sequence 1 - L2 sequence (such as the amino acid sequence represented by SEQ ID NO: 2) - antigen recognition sequence 2 - L3 sequence (such as the amino acid sequence represented by SEQ ID NO: 3) - antigen recognition sequence 3 - L4 sequence (such as the amino acid sequence represented by SEQ ID NO: 4).

The present application relates to a kind of anti-CD276 nanobody, the anti-CD276 nanobody includes complementary determining region CDR and framework region FR;Wherein, the complementary determining region CDR includes complementary determining region CDR1-CDR3;The framework region FR includes framework region FR1-FR5.The anti-human CD276 nanobody provided by the present application has the immunoreaction characteristic with CD276 antigen, and specificity is good, and affinity is high, can be applied to the preparation of CD276 detection reagent or antitumor drug etc., the anti-human CD276 nanobody provided by the present application can be used as the antigen recognition domain of CAR Then the construction of CAR-T cell, it has significant killing effect to the multiple tumor cell lines of expression CD276 antigen;The anti-human CD276 nanobody provided by the present application can be used to detect the expression of CD276 in tumor tissue.

Provided is a modified regulatory T cell capable of recognizing cells of the liver, capable of treating and / or preventing transplant rejection or immune-mediated damage, and capable of promoting regeneration of cells of the liver.SOLUTION: The present invention provides engineered regulatory T cells (Tregs) comprising a chimeric antigen receptor (CAR), wherein said CAR comprises an antigen recognition domain that specifically binds to the asialoglycoprotein receptor (ASGR). The invention also provides a method of promoting liver tissue repair and / or regeneration in a subject, said method comprising administering to said subject a modified Treg comprising a CAR, or a pharmaceutical composition comprising said modified Treg, wherein said CAR comprises a liver-specific antigen recognition domain.SELECTED DRAWING: None

Provided herein are CasX:gNA systems, and compositions and methods relating thereto, the systems comprising CasX proteins, guide nucleic acids (gNAs), and optionally donor template nucleic acids useful for the modification cell genes encoding proteins involved in antigen processing, antigen presentation, antigen recognition, and / or antigen response, as well as methods of producing and using populations of cells comprising these modified genes. In some embodiments, the modified cells further express chimeric antigen receptors (CAR) or engineered T cell receptors (TCR). Such systems are useful for preparing cells for immunotherapy.

Provided are a CD19-targeting humanized antibody and chimeric antigen receptor, and the use thereof. The humanized antibody contains CD19 VH and CD19 VL which are selected from one of groups 1) to 8). The CD19-targeting chimeric antigen receptor contains a CD19-targeting extracellular antigen recognition domain, a hinge region, a transmembrane region, and an intracellular domain, wherein the CD19-targeting extracellular antigen recognition domain contains CD19 VH and CD19 VL which are selected from one of groups 1) to 8).

The invention provides a plasmid for expressing a chimeric antigen receptor (CAR), a gamma delta-T cell and application, and relates to the technical field of biology. According to the plasmid for expressing the CAR, the expression efficiency of various promoters in gamma delta-T cells is compared, the promoter most suitable for the cell type is screened out, and the result shows that the SFFV promoter has the optimal expression performance. Compared with EF1 alpha and NMD, the promoter provided by the invention has higher transduction efficiency. The invention provides a structurally optimized CAR-gamma delta-T cell and a construction method thereof. The CAR structure comprises a combination of an antigen recognition structural domain driven by an SFFV promoter to express, a CD28 transmembrane structural domain and a DAP10 costimulatory signal structural domain. According to the structural design, the expression efficiency of the CAR in the gamma delta-T cells can be remarkably improved, and the recognition capability of the gamma delta-T cells on specific antigens and the tumor cell killing activity are enhanced, so that the maximization of the anti-tumor efficiency is realized.

The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual. The antigen-recognizing receptor is exemplified by chimeric antigen receptors (CAR) be expressed on the surface of an immune effector cells. The system also includes hematopoietic cells resistant to recognition of the same antigen by the antigen-recognizing receptor.

This invention provides a bispecific chimeric antigen receptor targeting BCMA-CD19 and its application, wherein the bispecific chimeric antigen receptor comprises an extracellular antigen recognition domain; wherein: the extracellular antigen recognition domain comprises an anti-BCMA extracellular antigen recognition domain and an anti-CD19 extracellular antigen recognition domain; the anti-CD19 extracellular antigen recognition domain comprises CD19VH and CD19VL, which are selected from one of groups 1) to 8).

The application provides a monoclonal antibody for specifically detecting rotavirus and an application thereof, and is directed to epidemic strains of porcine rotavirus, and refers to the gene sequence of VP6 protein published in GenBank, further optimizes an antigen epitope, obtains a purified recombinant VP6 protein with antigenicity, and performs animal immunization, and successfully screens the monoclonal antibody capable of specifically recognizing the porcine rotavirus. The monoclonal antibody screened can effectively recognize the epidemic strains, has the broad-spectrum recognition, is superior to the commercially available antibody, has high antigen recognition target specificity, is low in non-specificity, and has clear sequence background, can be scaled up and produced, and has good commercial value.

The presently disclosed subject matter provides cells, compositions and methods for enhancing immune responses toward tumor antigens. It relates to cells comprising an antigen-recognizing receptor (e.g., a HIT receptor) and an inhibitory polynucleotide. These cells have improved activity and / or efficiency.

The presently disclosed subject matter provides cells, compositions, and methods for enhancing immune responses to tumor antigens. These cells comprise a first antigen-recognizing receptor that targets CD70. These cells have improved activity and / or efficiency. The present invention also provides a method for reducing tumor burden in a subject with renal cell carcinoma, pancreatic cancer, or ovarian cancer, comprising administering to the subject an effective amount of cells comprising a TCR-like fusion molecule that targets CD70.

The present application belongs to the technical field of cellular immunization engineering, and particularly relates to a polypeptide specifically recognizing PSCA and application thereof. The polypeptide provided by the present application specifically recognizes PSCA and has good affinity performance. The polypeptide specifically targeting PSCA provided by the present application can mark PSCA positive cells, combine with PSCA antigen and PSCA positive cells, and can be used as a detection reagent for PSCA molecules and an in-vivo tracing labeling reagent. The polypeptide specifically targeting PSCA provided by the present application can also be used in an extracellular antigen recognition region of a chimeric antigen receptor, and can be used in an immune cell treatment drug targeting PSCA to kill malignant tumors expressing PSCA. The polypeptide specifically recognizing PSCA of the present application is derived from a natural full human antibody, and compared with a mouse-derived antibody, a chimeric antibody and a humanized antibody, the immunogenicity is greatly reduced, and the safety can be maximally ensured in clinical application.

A workflow is presented herein which includes methods and computational systems and devices for providing 3D computational models of potential off-target peptides each positioned in a groove of an MHC molecule ("MHC-off-target models"), quantifying structural similarity between each potential off-target peptide to a target peptide based on a comparison of the MHC-off-target models to a 3D computational model of a target MHC-peptide complex ("MHC-target model"), and ranking the potential off-target peptides based on a structural similarity metric. Example methods and systems can be applied to solve bioinformatics and treatment development problems. The present disclosure also relates to compositions that involve isolated peptides, e.g., MAGEA3168-176 and / or WT1126-134 off-target peptides, and the use of such compositions in methods for assessing off-target effects of antigen-recognition molecules that target a MAGEA3168-176 and / or WT1126-134 peptide, as well as for selecting antigen-recognition molecules and enriching samples for antigen-recognition molecules that specifically bind the MAGEA3168-176 and / or WT1126-134.

The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target DLL3 and cells comprising such DLL3-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the DLL3-targeted antigen-recognizing receptors for treatment.

This invention provides a humanized antibody targeting CD19, a chimeric antigen receptor, and their uses. The humanized antibody comprises CD19VH and CD19VL, selected from groups 1) to 8). The chimeric antigen receptor targeting CD19 of this invention comprises an extracellular antigen recognition domain, a hinge region, a transmembrane region, and an intracellular domain targeting CD19. The extracellular antigen recognition domain targeting CD19 comprises CD19VH and CD19VL, selected from groups 1) to 8).

Provided are a bispecific chimeric antigen receptor targeting BCMA-CD19 and the use thereof. The bispecific chimeric antigen receptor comprises an extracellular antigen recognition domain; the extracellular antigen recognition domain comprises an anti-BCMA extracellular antigen recognition domain and an anti-CD19 extracellular antigen recognition domain; and the anti-CD19 extracellular antigen recognition domain comprises CD19 VH and CD19 VL, which are selected from one of groups 1) to 8).

The invention provides a screening method of an alpha-lactalbumin detection antibody and application of the screening method in alpha-lactalbumin detection and dairy product process authenticity evaluation, and relates to the technical field of dairy product process detection. The screening method of the detection antibody for recognizing the lactalbumin comprises the following steps: taking animal serum immunized by alpha-lactalbumin, carrying out affinity purification to obtain candidate antibodies, and carrying out primary screening and final screening on the candidate antibodies to obtain the detection antibody. The detection antibody screened by the method is highly specific to alpha-lactalbumin, cross reaction of other proteins in a milk matrix can be avoided, and the reliability of actual detection is ensured. According to the invention, a screened detection antibody is also utilized to construct a'hot processing parameter-ELISA antigen recognition performance 'correlation model, and an efficient technical means is provided for rapid traceability of hot processing technologies such as milk pasteurization and UHT technology.

The application provides an anti-CK8 nanobody, a polypeptide containing the nanobody and application thereof. A variable region in the amino acid sequence of the nanobody comprises three complementarity determining regions CDR and a framework region FR, the complementarity determining regions CDR comprising a complementarity determining region CDR1, a complementarity determining region CDR2 and a complementarity determining region CDR3, wherein the most important sites participating in antigen recognition and combination are RXXRXYX on the CDR1 and AASPAVSPPRDGRAFTY on the CDR3. The nanobody and the polypeptide thereof have high affinity and activity, can specifically recognize and combine CK8, and can be used for enrichment, removal and detection of CK8 and CK8 positive cells.

The present application relates to the technical field of medical detection, and particularly relates to a high-hook-capability and anti-interference HBP detection kit, which comprises R1 reagent and R2 reagent; 3-[3-(cholylamido propyl) dimethylamino] propanesulfonic acid inner salt and sodium dodecyl sulfate are used to prepare the reagent R1, and by adjusting the use ratio of the two, the mutual cooperation of the two can ensure the reaction sensitivity of the reagent and improve the anti-interference performance of the reagent; two kinds of latex microspheres with different particle sizes are used to coat two kinds of HBP antibodies with different antigen recognition epitopes in the reagent R2, which can not only ensure that the reagent has a wider detection range in the high value area and improve the hook capability, but also ensure the sensitivity of the kit; the activation system adopts the method of combining two activators of NHS and EDC, which can effectively improve the coupling efficiency. Meanwhile, the present application also provides a preparation method of the high-hook-capability and anti-interference HBP detection kit, which does not need centrifugation and resuspension operation steps, and the method operation is simpler and the production cost is lower.

The invention provides a specific monoclonal antibody for detecting rotavirus and application of the specific monoclonal antibody, aiming at an epidemic strain of porcine rotavirus, reference to a gene sequence of VP6 protein published by GenBank, antigen epitopes are further optimized, and purified recombinant VP6 protein with antigenicity is obtained for animal immunization. The monoclonal antibody capable of specifically recognizing the porcine rotavirus is successfully screened out. The monoclonal antibody obtained through screening can effectively recognize epidemic strains, has broad-spectrum recognition, is superior to commercially available antibodies, and has high antigen recognition target performance and low non-specificity. And the sequence background is clear, large-scale amplification and production can be carried out, and the method has good commercial value.

Various embodiments of the present application provide binding molecules for B-lymphocyte antigens (e.g., CD19 and CD20), including antigen recognizing receptors (e.g., CARs) that target B-lymphocyte antigens (e.g., CD19 and CD20). Embodiments of the present application also provide cells expressing such binding molecules, therapeutic compositions comprising such cells, and methods for treating diseases or disorders associated with B-lymphocyte antigens (e.g., CD19 and CD20), including hematological cancers, autoimmune diseases (e.g., multiple sclerosis and systemic lupus erythematosus).

A diagnostic, preventive, or therapeutic agent may be used for a myeloproliferative neoplasm. An antibody or a functional fragment thereof that binds to a cleaved mutant CALR protein, may include an antigen-recognition site in (a) a polypeptide chain having an amino acid sequence set forth in SEQ ID NO: 1 or (b) a polypeptide chain having an amino acid sequence having deletion, substitution, or addition of one to several amino acids in SEQ ID NO: 1; and a diagnostic, preventive, or therapeutic agent for a myeloproliferative neoplasm containing the antibody.

The invention provides a screening method of lactoferrin detection antibody pairs and application of the screening method in lactoferrin detection and dairy product process authenticity evaluation, and relates to the technical field of dairy product process detection. The screening method of the lactoferrin detection antibody pair comprises the following steps: immunizing an animal with lactoferrin, then obtaining a monoclonal antibody through a hybridoma technology, obtaining a polyclonal antibody through affinity purification, carrying out cross combination on the monoclonal antibody and the polyclonal antibody to form a candidate antibody pair, and screening the candidate antibody pair to obtain the lactoferrin detection antibody pair. And carrying out primary screening, medium screening and final screening on the candidate antibody pair to obtain a detection antibody pair. The detection antibody pair screened by the method provided by the invention can specifically identify lactoferrin, can avoid cross reaction of other proteins in a milk matrix, and ensures the reliability of actual detection. The invention also utilizes the screened detection antibody to construct a hot processing parameter-lactoferrin antigen recognition relationship, and provides an efficient technical means for rapid traceability of hot processing technologies such as milk pasteurization, UHT technology and the like.

The present invention provides a method for producing CAR-T cells, the method comprising: a first step for stimulating a cell population containing unstimulated CAR-T cells under condition [A]; and a second step for stimulating a cell population containing CAR-T cells after the first step under condition [B]. [A] [Number of T cells (cells) in a cell population containing unstimulated CAR-T cells]:[Number of antigen recognition factors (pmol)]:[Number of costimulatory factors (pmol)] = 106:0.1-0.83:0.2-1.7; [B] [Number of T cells (cells) in a cell population containing CAR-T cells after first step]:[Number of antigen recognition factors (pmol)]:[Number of costimulatory factors (pmol)] = 106:0.05-0.17:0.05-0.28 (provided that the sum of the number of antigen recognition factors and the number of costimulatory factors in [B] is smaller than that in [A]).